LNCHC directly binds and regulates YBX1 stability to ameliorate metabolic dysfunction‐associated steatotic liver disease progression

Documenti analoghi

• Utilizing Extracellular Vesicles from as a Novel Approach for Protecting the Skin from Oxidative Damage.
  di: Xu, Ran, et al.
  Pubblicazione: (2025)
• Associations of serum carotenoids with cardiovascular disease mortality among patients with metabolic dysfunction‐associated steatotic liver disease
  di: Qian‐Qian Wang, et al.
  Pubblicazione: (2025)
• Chitosan and chito-oligosaccharides as multifunctional therapeutics for metabolic dysfunction-associated steatotic liver disease (MASLD).
  di: Zhou, Gaoli, et al.
  Pubblicazione: (2026)
• The depletion of serine beta‐lactamase‐like protein (LACTB) ameliorates metabolic dysfunction–associated steatotic liver disease by reducing ubiquitin‐mediated degradation of carnitine palmitoyltransferase 2
  di: Wujiang Shi, et al.
  Pubblicazione: (2026)
• Health information in short videos about metabolic dysfunction‐associated steatotic liver disease: Analysing quality and reliability
  di: Ruihao Ding, et al.
  Pubblicazione: (2024)